Tosymra is a drug owned by Tonix Medicines Inc. It is protected by 8 US drug patents filed from 2019 to 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 19, 2031. Details of Tosymra's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9211282 | Formulations comprising triptan compounds |
Jul, 2031
(6 years from now) | Active |
| US9974770 | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) | Active |
| US11337962 | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) | Active |
| US10603305 | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) | Active |
| US9610280 | Formulations comprising triptan compounds |
Jun, 2030
(5 years from now) | Active |
| US8268791 | Alkylglycoside compositions for drug administration |
May, 2026
(1 year, 5 months from now) | Active |
| US9283280 | Compositions for drug administration |
May, 2026
(1 year, 5 months from now) | Active |
| US8440631 | Compositions for drug administration |
May, 2026
(1 year, 5 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tosymra's patents.
Latest Legal Activities on Tosymra's Patents
Given below is the list of recent legal activities going on the following patents of Tosymra.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 14 May, 2024 | US10603305 |
| Change in Power of Attorney (May Include Associate POA) Critical | 07 May, 2024 | US9974770 |
| Email Notification Critical | 07 May, 2024 | US9974770 |
| Change in Power of Attorney (May Include Associate POA) Critical | 25 Apr, 2024 | US11337962 |
| Email Notification Critical | 25 Apr, 2024 | US11337962 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US9610280 |
| Email Notification Critical | 24 Apr, 2024 | US10603305 |
| Email Notification Critical | 24 Apr, 2024 | US9610280 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US9211282 |
| Change in Power of Attorney (May Include Associate POA) Critical | 24 Apr, 2024 | US10603305 |
US patents provide insights into the exclusivity only within the United States, but Tosymra is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tosymra's family patents as well as insights into ongoing legal events on those patents.
Tosymra's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tosymra's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 19, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tosymra Generic API suppliers:
Sumatriptan is the generic name for the brand Tosymra. 5 different companies have already filed for the generic of Tosymra, with Lannett Co Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tosymra's generic
Alternative Brands for Tosymra
Tosymra which is used for managing acute migraine episodes., has several other brand drugs in the same treatment category and using the same active ingredient (Sumatriptan). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Sumatriptan. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Currax |
| |
| Endo Operations |
| |
| Glaxosmithkline |
| |
| Meridian Medcl |
| |
| Teva Branded Pharm |
| |
| Tonix Meds |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Sumatriptan, Tosymra's active ingredient. Check the complete list of approved generic manufacturers for Tosymra
About Tosymra
Tosymra is a drug owned by Tonix Medicines Inc. It is used for managing acute migraine episodes. Tosymra uses Sumatriptan as an active ingredient. Tosymra was launched by Tonix Meds in 2019.
Approval Date:
Tosymra was approved by FDA for market use on 25 January, 2019.
Active Ingredient:
Tosymra uses Sumatriptan as the active ingredient. Check out other Drugs and Companies using Sumatriptan ingredient
Treatment:
Tosymra is used for managing acute migraine episodes.
Dosage:
Tosymra is available in spray form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/SPRAY | SPRAY | Prescription | NASAL |